1-2 of 2
Jan-Paul de Boer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Clinical Trials & Observations
Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jäger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6266–6274.
https://doi.org/10.1182/bloodadvances.2023010334
Published: 2023
Includes: Supplemental data
Journal Articles

Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair

Cathelijn E. M. Aarts, Ida H. Hiemstra, Eelke P. Béguin, Arjan J. Hoogendijk, Souhailla Bouchmal, Michel van Houdt, Anton T. J. Tool, Erik Mul, Machiel H. Jansen, Hans Janssen, Floris P. J. van Alphen, Jan-Paul de Boer, Charlotte L. Zuur, Alexander B. Meijer, Timo K. van den Berg, Taco W. Kuijpers
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3562–3574.
https://doi.org/10.1182/bloodadvances.2019031609
Published: 2019
Includes: Multimedia, Supplemental data